Hospitalist Doctors in Flint, MI Accepting Medicare

5 Hospitalist doctors found. Showing 1 - 5

Swathi Gorle, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: Hurley Medical Center, 1 Hurley Plaza, Flint, MI 48503 Phone: 810-262-9080

Veni Jhansi Peram, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2486 Nerredia St Ste E, Flint, MI 48532 Phone: 810-230-9901    Fax: 810-230-9916

Alpesh K Korant, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1119 Villa Linde Ct Ste 37, Flint, MI 48532 Phone: 810-732-7460    Fax: 810-732-0466

Sandip Karki, MD Hospitalist Medicare: Medicare Enrolled Practice Location: G3230 Beecher Rd Ste 2, Flint, MI 48532 Phone: 810-342-5800    Fax: 810-342-5810

Dr. Himabindu B Yarlagadda, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 420 S Saginaw St, Flint, MI 48502 Phone: 810-232-3522

News Archive

Diets rich in copper and trans fats increase the risk of mental decline

Researchers say that elderly people whose diets are rich in copper and heavy in saturated fats and trans fats increase their risk of a cognitive decline that could be related to the onset of Alzheimer's disease.

FDA grants 510(k) clearance for Ventana Ki-67 image analysis algorithm

Ventana Medical Systems, Inc., a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm Ki-67 (30-9) image analysis application used with the VENTANA iScan Coreo Au scanner running VIRTUOSO software.

IPC to distribute AP's Promescent in US for treatment of premature ejaculation

The Independent Pharmacy Cooperative and Absorption Pharmaceuticals have signed a distribution agreement whereby IPC will make AP's topical treatment for premature ejaculation, Promescent, available to its 4,500+ member pharmacies throughout the United States.

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

Oncologists combine two different types of immunotherapy to successfully treat metastatic melanoma

Oncologists at the Fred Hutchinson Cancer Research Center have successfully treated a patient with metastatic melanoma by combining two different types of immunotherapy. Cassian Yee and colleagues describe their approach in a paper, "Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient," that will be published online May 30 in The Journal of Experimental Medicine.

Read more Medical News

› Verified 4 days ago